Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 3Carcinoma 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Prostatic Neoplasms 1Primary Myelofibrosis 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Fibrolamellar hepatocellular carcinoma 1Diabetes Mellitus, Insulin-Dependent, 12 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Biliary Tract Neoplasms 1Adenocarcinoma 1

Interventions

Paclitaxel 2tremelimumab 1trastuzumab deruxtecan 1poly ICLC 1pembrolizumab 1osimertinib 1eribulin 1durvalumab 1cemiplimab 1Vascular Endothelial Growth Factor A 1Radiotherapy 1Peptides 1Doxorubicin 1Docetaxel 1Carboplatin 1Capecitabine 1Bevacizumab 1Antibodies, Bispecific 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Diabetes Mellitus, Insulin-Dependent, 12 × poly ICLC × Clear all
NCT06564623 2026-05-08

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Recruiting
25 enrolled
Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Biliary Tract Neoplasms, Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡